Disclosures for "Characterization of Antibiotic Prophylaxis Risk Mitigation Practices Across Eculizumab and Ravulizumab Adult, Phase III Clinical Trials for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder"
-
Dr. Akpoji has received personal compensation for serving as an employee of Alexion, AstraZeneca Rare Disease. Dr. Akpoji has or had stock in Alexion, AstraZeneca Rare Disease.
-
Dr. Pandya has received personal compensation for serving as an employee of Alexion, Astra Zeneca Rare Disease. Dr. Pandya has received personal compensation for serving as an employee of Rhythm Pharmaceuticals. Dr. Pandya has stock in Sanofi. Dr. Pandya has stock in Alexion, Astra Zeneca Rare Disease.
-
Rasha Aguzzi has received personal compensation for serving as an employee of Alexion Pharmaceutical. Rasha Aguzzi has or had stock in AstraZeneca.
-
Dr. Stankowski has nothing to disclose.
-
Sami Fam has received personal compensation for serving as an employee of Alexion Pharmaceuticals. Sami Fam has or had stock in Astra Zeneca.
-
Dr. Mujeebuddin has received personal compensation for serving as an employee of Alexion AstraZeneca Rare Disease. Dr. Mujeebuddin has stock in AstraZeneca.
-
Dr. Jha has received personal compensation for serving as an employee of Alexion Pharmaceuticals. Dr. Jha has or had stock in Alexion Pharmaceuticals.